HIGHLIGHTS
- who: Alberto Aimo from the Institute of Life Sciences, Scuola Superiore Sant`Anna, Piazza Martiri della Libertu00e0, Pisa, Italy have published the Article: The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction, in the Journal: (JOURNAL)
- future: Future research should try to elucidate whether vericiguat or sacubitril/valsartan is more effective compared to the combination of ACEi/ARB beta-blockers and MRA in patients with chronic HF.
SUMMARY
PDE3 inhibitors, such as milrinone and enoximone, are used in acute HF (AHF), and PDE5 inhibitors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.